The microRNA-34 Family and Its Functional Role in Lung Cancer
This study describes the regulatory role of the miR-34 family in lung cancer and the associated research advances in treatment.PMID:38700126 | DOI:10.1097/COC.0000000000001106 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 3, 2024 Category: Cancer & Oncology Authors: Tinghua Zhang Youyuan Hu Na Yang Shaofu Yu Xingxiang Pu Source Type: research
Knockdown of NADK promotes LUAD ferroptosis via NADPH/FSP1 axis
CONCLUSIONS: NADK is over-expressed in LUAD patients. Knockdown of NADK inhibited the proliferation of LUAD cells both in vitro and in vivo and promotes the Erastin/RSL3-induced ferroptosis of LUAD cells by down-regulating the NADPH/FSP1 axis.PMID:38700533 | DOI:10.1007/s00432-024-05752-z (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 3, 2024 Category: Cancer & Oncology Authors: Xiangpeng Meng Fang Peng Shijie Yu Xinming Chi Wenchi Wang Shujuan Shao Source Type: research
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
CONCLUSION: To our knowledge, this first, prospective US cooperative group, multicenter study demonstrates that MRDneg at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.PMID:38701390 | DOI:10.1200/JCO.23.00934 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 3, 2024 Category: Cancer & Oncology Authors: Marcelo C Pasquini Paul K Wallace Brent Logan Manmeet Kaur Joseph D Tario Alan Howard Yali Zhang Claudio Brunstein Yvonne Efebera Nancy Geller Sergio Giralt Parameswaran Hari Mary M Horowitz John Koreth Amrita Krishnan Heather Landau George Somlo Nina Sha Source Type: research
Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non-small cell lung cancer in real-world practice
CONCLUSIONS: Neoadjuvant treatment with a combination of immunotherapy plus chemotherapy appears to achieve higher radiological and pathological responses than monotherapy for IIA-IIIB NSCLC. Log-rank analysis showed that a better outcome could be expected in patients with the addition of immunotherapy to neoadjuvant chemotherapy if compared with patients with chemotherapy alone in terms of DFS.PMID:38693705 | DOI:10.1111/crj.13761 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 2, 2024 Category: Cancer & Oncology Authors: Xiaojie Huang Guanchao Pang Zhirong Mao Baizhou Li Zhihua Teng Yan Yang Zijian Qiu Xiuxiu Chen Pingli Wang Source Type: research
A randomized phase III trial of postoperative surveillance for pathological stage II and IIIA non-small cell lung cancer (JCOG2012, PHOENIX)
Jpn J Clin Oncol. 2024 May 1:hyae056. doi: 10.1093/jjco/hyae056. Online ahead of print.ABSTRACTThe goal of postoperative surveillance following non-small cell lung cancer surgery is to detect recurrence and second primary malignancies while curative treatment is still possible. Although several guidelines recommend that patients have computed tomography (CT) scans every 6 months for the first 2 years after resection, then once a year, there is no evidence that it is effective for survival, especially in locally advanced non-small cell lung cancer. In October 2022, we launched a multi-institutional, randomized controlled ph...
Source: Clinical Lung Cancer - May 2, 2024 Category: Cancer & Oncology Authors: Kenta Tane Satoshi Shiono Masashi Wakabayashi Tomoko Kataoka Noriko Mitome Haruhiko Fukuda Keiju Aokage Shun-Ichi Watanabe In behalf of the Lung Cancer Surgical Study Group/Japan Clinical Oncology Group Source Type: research
Fractionated stereotactic radiotherapy of intracranial postoperative cavities after resection of brain metastases - Clinical outcome and prognostic factors
CONCLUSION: FSRT after surgical resection of BM is an effective and safe treatment approach with excellent local control and acceptable toxicity. Further prospective randomized trials are needed to establish standardized therapeutic guidelines.PMID:38694237 | PMC:PMC11061678 | DOI:10.1016/j.ctro.2024.100782 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 2, 2024 Category: Cancer & Oncology Authors: L Hahnemann A Kr ämer C Fink C Jungk M Thomas P Christopoulos J W Lischalk J Meis J H örner-Rieber T Eichkorn M Deng K Lang A Paul E Meixner F Weykamp J Debus L K önig Source Type: research
Primary lung cancer in children and adolescents
CONCLUSIONS: Primary lung cancer in children and adolescents are rare and histopathological heterogeneous. Persistent GGO nodules may indicate early-stage lung adenocarcinoma in children and adolescents.PMID:38695944 | DOI:10.1007/s00432-024-05750-1 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 2, 2024 Category: Cancer & Oncology Authors: Qiuming Chen Jun Cheng Luming Wang Xiayi Lv Jian Hu Source Type: research
CXCR6-positive circulating mucosal-associated invariant T cells can identify patients with non-small cell lung cancer responding to anti-PD-1 immunotherapy
CONCLUSION: CD8+MAIT cells are a potential predictive biomarker for patients with NSCLC responding to anti-PD-1 therapy. The correlation between CD8+MAIT cells and immunotherapy sensitivity may be ascribed to high CXCR6 expression.PMID:38698468 | DOI:10.1186/s13046-024-03046-3 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 2, 2024 Category: Cancer & Oncology Authors: Jingjing Qu Binggen Wu Lijun Chen Zuoshi Wen Liangjie Fang Jing Zheng Qian Shen Jianfu Heng Jianya Zhou Jianying Zhou Source Type: research
Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non-small cell lung cancer in real-world practice
CONCLUSIONS: Neoadjuvant treatment with a combination of immunotherapy plus chemotherapy appears to achieve higher radiological and pathological responses than monotherapy for IIA-IIIB NSCLC. Log-rank analysis showed that a better outcome could be expected in patients with the addition of immunotherapy to neoadjuvant chemotherapy if compared with patients with chemotherapy alone in terms of DFS.PMID:38693705 | DOI:10.1111/crj.13761 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 2, 2024 Category: Cancer & Oncology Authors: Xiaojie Huang Guanchao Pang Zhirong Mao Baizhou Li Zhihua Teng Yan Yang Zijian Qiu Xiuxiu Chen Pingli Wang Source Type: research
A randomized phase III trial of postoperative surveillance for pathological stage II and IIIA non-small cell lung cancer (JCOG2012, PHOENIX)
Jpn J Clin Oncol. 2024 May 1:hyae056. doi: 10.1093/jjco/hyae056. Online ahead of print.ABSTRACTThe goal of postoperative surveillance following non-small cell lung cancer surgery is to detect recurrence and second primary malignancies while curative treatment is still possible. Although several guidelines recommend that patients have computed tomography (CT) scans every 6 months for the first 2 years after resection, then once a year, there is no evidence that it is effective for survival, especially in locally advanced non-small cell lung cancer. In October 2022, we launched a multi-institutional, randomized controlled ph...
Source: Clinical Lung Cancer - May 2, 2024 Category: Cancer & Oncology Authors: Kenta Tane Satoshi Shiono Masashi Wakabayashi Tomoko Kataoka Noriko Mitome Haruhiko Fukuda Keiju Aokage Shun-Ichi Watanabe In behalf of the Lung Cancer Surgical Study Group/Japan Clinical Oncology Group Source Type: research
Fractionated stereotactic radiotherapy of intracranial postoperative cavities after resection of brain metastases - Clinical outcome and prognostic factors
CONCLUSION: FSRT after surgical resection of BM is an effective and safe treatment approach with excellent local control and acceptable toxicity. Further prospective randomized trials are needed to establish standardized therapeutic guidelines.PMID:38694237 | PMC:PMC11061678 | DOI:10.1016/j.ctro.2024.100782 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 2, 2024 Category: Cancer & Oncology Authors: L Hahnemann A Kr ämer C Fink C Jungk M Thomas P Christopoulos J W Lischalk J Meis J H örner-Rieber T Eichkorn M Deng K Lang A Paul E Meixner F Weykamp J Debus L K önig Source Type: research
WNT5B drives osteosarcoma stemness, chemoresistance and metastasis
CONCLUSIONS: Together, these data define WNT5B's role in driving osteosarcoma cancer stem cell expansion and methotrexate resistance and provide evidence that the WNT5B pathway is a promising candidate for treating osteosarcoma patients.KEY POINTS: WNT5B expression is high in osteosarcoma stem cells leading to increased stem cell proliferation and migration through SOX2. WNT5B expression in stem cells increases rates of osteosarcoma metastasis to the lungs and liver in vivo. The hyaluronic acid degradation enzyme HYAL1 is regulated by WNT5B in osteosarcoma contributing to metastasis. Inhibition of WNT5B with a ROR1 antibod...
Source: Clinical Lung Cancer - May 1, 2024 Category: Cancer & Oncology Authors: Rachel S Perkins Glenn Murray Sarocha Suthon Lindsey Davis Nicholson B Perkins Lily Fletcher Amanda Bozzi Saylor L Schreiber Jianjian Lin Steven Laxton Rahul R Pillai Alec J Wright Gustavo A Miranda-Carboni Susan A Krum Source Type: research
Enhancing anticancer activity of macrophages through rational drug combinations
J Clin Invest. 2024 May 1;134(9):e180512. doi: 10.1172/JCI180512.ABSTRACTTargeting tumor-associated macrophages (TAMs) is an emerging approach being tested in multiple clinical trials. TAMs, depending on their differentiation state, can exhibit pro- or antitumorigenic functions. For example, the M2-like phenotype represents a protumoral state that can stimulate tumor growth, angiogenesis, metastasis, therapy resistance, and immune evasion by expressing immune checkpoint proteins. In this issue of the JCI, Vaccaro and colleagues utilized an innovative drug screen approach to demonstrate that targeting driver oncogenic signa...
Source: Clinical Lung Cancer - May 1, 2024 Category: Cancer & Oncology Authors: Gordon B Mills Marilyne Labrie Source Type: research
Thyroid abnormalities identified on CT screening for lung cancer
CONCLUSION: ITNs are detected at LDCT however, no malignancy was found. Certain predictors for ITNs in females have been identified including breast density, which may point towards a common causal pathway.PMID:38691910 | DOI:10.1016/j.clinimag.2024.110162 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 1, 2024 Category: Cancer & Oncology Authors: Maaike van Gerwen Teng Ma Rowena Yip Chris Choi Natela Paksashvili David Yankelevitz Claudia Henschke Source Type: research
Smoking-Related Interstitial Lung Disease: Historical Perspective and Advances in the Twenty-first Century
Surg Pathol Clin. 2024 Jun;17(2):159-171. doi: 10.1016/j.path.2023.11.003. Epub 2023 Dec 7.ABSTRACTIn the twenty- first century, there is widespread agreement that in addition to lung cancer, emphysema, and chronic bronchitis, cigarette smoking causes accumulation of pigmented macrophages, interstitial fibrosis, and Langerhans cell proliferation in various permutations. These histologic changes remain subclinical in some patients and produce clinical manifestations and imaging abnormalities in others. Debate surrounds terminology of these lesions, which are often grouped together under the umbrella of "smoking-related inte...
Source: Clinical Lung Cancer - May 1, 2024 Category: Cancer & Oncology Authors: Sanjay Mukhopadhyay Irene Sansano Source Type: research
